What is the primary business of Regeneron Pharmaceuticals, Inc. based on this 1997 filing?

Based on the filing context as an annual report for a biotechnology company, Regeneron Pharmaceuticals, Inc. is primarily engaged in the research, development, and potential commercialization of novel therapeutic products.

What financial information can investors expect to find in this 10-K/A filing?

Investors can expect to find detailed financial statements including balance sheets, income statements, and cash flow statements, along with accompanying notes. This information will provide insights into the company's revenues, expenses, profitability, and financial position as of and for the year ended December 30, 1996.

What are the key risks associated with investing in Regeneron Pharmaceuticals, Inc. as outlined in this filing?

While specific risks are detailed within the full report, typical risks for a biotechnology company at this stage include the inherent uncertainties of drug development, clinical trial success, regulatory approvals, competition, intellectual property protection, and the ability to secure future funding for ongoing research and development.

Why is this filing an amendment (10-K/A)?

An 'A' designation for a 10-K filing typically indicates that it is an amendment. This means that the company is filing to correct or supplement information previously submitted in an earlier filing for the same period. Investors should review both the original filing and the amendment to understand the complete and updated information.

REGN 10-K FY1996 Annual Report — Revenue, Net Income, EPS

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed this 10-K/A amendment on May 30, 1997, for the period ending December 30, 1996. As a biotechnology company, its focus would be on research and development of novel therapeutics. Investors would be keen to understand the company's progress in its drug pipeline, clinical trials, and potential for future commercialization. The filing likely details financial performance, risk factors, and management's outlook, all crucial for assessing the company's growth prospects and investment potential in the rapidly evolving biotech sector.

Key Highlights

1This filing is an amendment (10-K/A) to Regeneron Pharmaceuticals, Inc.'s annual report for the fiscal year ending December 30, 1996.
2The filing date was May 29, 1997, indicating a retrospective look at the company's performance and status in 1996.
3As a biotechnology company, investors would focus on details regarding its research and development pipeline, intellectual property, and regulatory progress.
4The financial statements and management discussion within the report provide insights into the company's revenue, expenses, cash flow, and overall financial health.
5Risk factors discussed in the report are critical for understanding potential challenges and uncertainties facing the company.
6This report provides a snapshot of Regeneron's operational and financial landscape as it existed at the close of 1996, crucial for tracking its historical trajectory.

REGENERON PHARMACEUTICALS, INC. Annual Report (Amendment), Year Ended Dec 31, 1996

Summary

Key Highlights

Frequently Asked Questions